Expert Interview
Discussing expectations for efficacy/safety for Jazz Pharmaceutical's HERIZON-GEA-01 trial evaluating zanidatamab combinations in 1L HER2+ gastroesophageal adenocarcinomas (GEAs)
Ticker(s): JAZZ, ZYMEInstitution: Henry Ford Health
- GI oncologist at Henry Ford Health and Professor of Internal Medicine at Michigan State University School of Medicine
- Manages 20+ patients with gastroesophageal adenocarcinomas
- Leads the GI clinical trials program for Henry Ford Health Institute
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
